KCT0006600尚未招募未知
Anti-obesity effect of Bangpungtongseong-san and Daeshiho-tang: Randomized, Double blind clinical trial
Dongguk University Ilsan Oriental Hospital0 个研究点目标入组 146 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19?(Year) 至 65?(Year)（—）
- 性别
- All
入选标准
- •(1) Those who aged 19 to 65
- •(2) Those with BMI=27kg/m2, or with BMI=25kg/m2 and at least one of the risk factors for metabolic diseases such as high blood pressure, diabetes, and hyperlipidemia.
- •- Hypertension: Those diagnosed with high blood pressure and receiving appropriate treatment, or those whose blood pressure measured during screening is over than 140 mmHg of sBP or over than 90 mmHg of dBP three consecutive times
- •- Diabetes mellitus: Those diagnosed with diabetes mellitus and receiving appropriate treatment, or those with fasting glucose=126 mg/dL at the time of screening
- •- Dyslipidemia: Those diagnosed with dyslipidemia and receiving appropriate treatment, or those whose total cholesterol (TC) measured during screening is over than 200 mg/dL or triglyceride (TG) is over than 200 mg/dL
- •(3) Those who have not tried to lose weight in the last 1 month
- •(4) Those who don’t meet the exclusion criteria and are generally in good health
- •(5) Non-smoker (a person who has quit smoking for at least one year if he/she has smoked in the past)
- •(6) Those who have not taken probiotics and antibiotics in the last 1 month
- •(7) Those who have received sufficient explanation prior to participating in the test and have signed a written agreement approved by the IRB to participate in the study according to his/her free will.
排除标准
- •(1) Those who have a change of more than 10% of his/her previous body weight within the last 3 months
- •(2) Patients with endocrine diseases that may affect body weight such as hypothyroidism and Cushing’s syndrome
- •(3) Patients with heart disease (heart failure, angina pectoris, myocardial infarction)
- •(4) Patients with malignant tumor or lung disease
- •(5) Patients diagnosed with liver dysfunction (ALT, AST = 2.5 times normal upper limit)
- •(6) Patients with cholelithiasis
- •(7) Patients diagnosed with severe renal failure (Cr > 2.0mg/dL)
- •(8) Those who have taken probiotics and antibiotics in the last 1 month
- •(9) Patients with a history of neurological or psychological significance or current illness (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, anorexia nervosa, etc.) or those on medication for the central nervous system
- •(10) Patients with a history of stroke or temporary ischemic heart attack
- •(11) Patients with history of basic eating disorders such as anorexia nervosa or bulimia nervosa
- •(12) Patients who have taken medication that can affect weight, such as central weight loss agents, appetite suppressants, laxatives or oral steroids, thyroid hormones, amphetamines, ciproheptadine, phenodiazine or drugs that affect absorption, metabolism, and excretion within the last three months
- •(13) Patients on medication that may be abused or receiving other prohibited treatments (antidepressant, antiserotonin, barbiturate, antipsychotics, drugs)
- •(14) Patients with anatomical changes such as resection that are difficult to assess
- •(15) Patients who have had surgery to lose weight: gastroplasty, etc.
- •(16) Pregnant women, nursing mothers, women of childbearing potential who have plan for pregnant or who do not agree to the appropriate method of birth control (for example, oral contraceptives, hormonal transplants, IUDs, spermicide barrier methods, condoms, abstinence, etc.)
- •(17) Those with a history of serious alcohol or drug abuse within the past 1 year
- •(18) Those who are allergic to or overreacting to a clinical trial drug
- •(19) Patients who have taken other test drugs within the last month
- •(20) Those who are not willing or unable to comply with the living guidelines and precautions described in this plan
- •(21) Those who are deemed inappropriate by the tester
研究者
相似试验
尚未招募
不适用
A study of Daesiho-tang on weight loss in Obese Patients with non-alcoholic fatty liver diseaseEndocrine, nutritional and metabolic diseaseKCT0003554Dunsan Korean Medicine Hospital of Daejeon University60
尚未招募
Unknown
Investigation on the anti-obesity effects of research food intakeJPRN-UMIN000054009Metagen, Inc.20
尚未招募
2 期
To Compare the efficacy of Full body steaming and Safoof Mohazil and Arq Zeera in patients with ObesityCTRI/2023/07/054770Central Council for Research in Unani Medicine New Delhi
已完成
不适用
Investigating the effects of the herbal medicine Taeeumjowui-tang on obesity and metabolic syndrome risk factorsISRCTN13677132Cheonan Oriental Hospital of Daejeon University206
已完成
不适用
Dose-dependent anti-obesity effect of the plant extract in subjects with abdominal obesityHealthy volunteersJPRN-UMIN000020188Hiroshima University60